The target blood pressure in patients with diabetes is <130 mm Hg
|
|
- Dulcie Richard
- 6 years ago
- Views:
Transcription
1 Controversies in hypertension, About Diabetes diabetes and and metabolic Cardiovascular syndrome Risk ESC annual congress August 29, 2011 The target blood pressure in patients with diabetes is <130 mm Hg Pro Lars Rydén Karolinska Institutet Stockholm, Sweden
2 Diabetes Lars Rydén and the Heart Karolinska Institutet Stockholm Meet the experts Sweden Disclosures August Research grants The Swedish Heart Lung Foundation The Swedish Medical Research Council AFA Insurance Queen Victoria's and King Gustav V Research Fund Karolinska Institutet Stockholm County Council Sanofi-aventis Astrazeneca Hoffman-LaRoche Honoraria for advisory boards, steering committees, lectures DSMB positions (RELY-ABLE; RED-HF) Exec Steering Committees (ACE; ORIGIN; ALECARDIO; REWIND) Lectures by various Swedish organizations Lectures by various commercial companies
3 The target blood presssure in patients with diabetes is <130 mm Hg Guideline recommendations On the background to these recommendations Epidemiological information Myocardial involvement Blood pressure lowering treatment Conclusion
4 The target blood presssure in patients with diabetes is <130 mm Hg Guideline recommendations
5 Guideline recommendations Variable Treatment target (Chobanian et al JAMA 2003; 289: 2560)
6 Guideline recommendations Variable Treatment target (Graham et al Eur Heart J 2007; 28: 2375)
7 Guideline recommendations Variable Treatment target (Mancia et al Eur Heart J 2007; 28: 1462)
8 Guideline recommendations Variable Lifestyle modification Smoking cessation BP Treatment target Structured education Obligatory <130 / 80 mm Hg Renal dysf <125/75 HbA1c (DCCT standard) 6.5% mmol/l mg/dl Venous plasma glucose < Cholesterol < LDL < HDL male >1.0; female >1.2 40; 76 Triglycerides < (Rydén, Standl et al Eur Heart J 2007; 28: 88)
9 Guideline recommendations Variable Treatment target American Diabetes Association B C Supporting evidence from well-conducted cohort studies Supporting evidence from poorly controlled or uncontrolled trials Conflicting evidence with the weight of evidence supporting the recommendation (ADA Diabetes Care; 34: Suppl 1 January 2011)
10 The target blood presssure in patients with diabetes is <130 mm Hg Guideline recommendations On the background to these recommendations Epidemiological information
11 Epidemiological considerations Hypertension and diabetes co-exist too often to be a play of chance Hypertension in patients with diabetes 70 90% Diabetes in patients with hypertension 20 50% (Rydén et al Blood Pressure 2008; 17: 250)
12 Epidemiological considerations Hypertension and diabetes co-exist too often to be a play of chance People with either hypertension or type 2 diabetes are at an increased risk for premature cardiovascular morbidity/mortality The presence of both conditions increases this risk 2 4 times Blood pressure and hyperglycemia are continuous variables (Rydén et al Blood Pressure 2008; 17: 250)
13 Hypertension, Diabetes and Cardiovascular Risk About Diabetes and Cardiovascular Risk 10-year CHD mortality/ person years Rate 250 All patients RR= Patients with diabetes RR=3.2 RR=2.8 RR= RR=4.4 RR=3.4 0 < >200 Systolic blood pressure (mm Hg) (Stamler et al. Diabetes Care. 1993;16:434)
14 The target blood presssure in patients with diabetes is <130 mm Hg Guideline recommendations On the background to these recommendations Epidemiological information Myocardial involvement
15 Myocardial involvement in diabetes Possible interactions with high blood pressure Structural abnormalities Myocyte hypertrophy Deposition of PAS-positive glycoproteins Interstitial edema Extracellular matrix accumulation Myocyte loss and interstitial fibrosis Intramyocardial microangiopathy Not specific for patients with diabetes (Shehadeh & Regan Clin Card 1995; 18:301; Hardin Cor Artery Disease 1996; 7:99)
16 Diabetes mellitus and hypertension Effects on left ventricular structure and function The STRONG Heart Study American Indians n= Without diabetes or hypertension With diabetes only 642 With hypertension only 614 With diabetes and hypertension 874 Method Echocardiography (Bella et al Am J Card 2001:87;1260)
17 Diabetes mellitus and hypertension Effects on left ventricular structure and function The STRONG Heart Study % Proportion with left ventricular hypertrophy Gender specific criteria LV mass/height (g/m 2 ) No HTN or DM DM HTN HTN and DM (Bella et al Am J Card 2001:87;1260)
18 Diabetes mellitus and hypertension Effects on left ventricular structure and function The STRONG Heart Study % 16 Proportion with subnormal left ventricular function Stress corrected LV midwall shortening (%) No HTN or DM DM HTN HTN and DM (Bella et al Am J Card 2001:87;1260)
19 Diabetes mellitus and hypertension Effects on left ventricular structure and function The STRONG Heart Study Conclusions Diabetes associated with increased LV mass independent of and additive to hypertension related to impaired LV systolic function independent of age, gender, BMI and heart rate Insulin resistance a possible common link (Bella et al Am J Card 2001:87;1260)
20 The target blood presssure in patients with diabetes is <130 mm Hg Guideline recommendations On the background to these recommendations Epidemiological information Myocardial involvement Blood pressure lowering treatment
21 Antihypertensive treatment in patients with diabetes Overview of different drugs Conclusions These overviews showed that the effect on major cardiovascular events of BP-lowering regimens studied were broadly comparable for patients with and without diabetes (Arch Intern Med 2005:165;1410)
22 Antihypertensive treatment in patients with diabetes Systolic Hypertension in the Elderly Program (SHEP) Patients without & 583 with type 2 diabetes Randomised treatment Chlortalidone + atenolol/reserpine Placebo & any prescription Follow up 5 years Mortality, stroke & MI Trial design (Curb et al JAMA 1996; 276: 1886)
23 Events no Antihypertensive treatment in patients with diabetes Systolic Hypertension in the Elderly Program (SHEP) Major cardiovascular events during follow up Active Placebo (Curb et al JAMA 1996; 276: 1886) Diabetes No diabetes Saved/
24 Antihypertensive treatment in patients with diabetes Hypertension Optimal Treatment (HOT) Patients without & with type 2 diabetes Treatment Felodipine + ACE-inhib or betablocker Target diastolic pressure 80; 85; 90 Follow up 3.8 years ( ) Trial design (Hansson et al Lancet 1998; 351:1755I)
25 Event rate/ 1000 patient years Antihypertensive treatment in patients with diabetes Hypertension Optimal Treatment (HOT) Nonfatal/fatal MI and stroke & all CV events All patients Patients with diabetes -51% <90 Diastolic blood pressure (mm Hg) (Hansson et al Lancet 1998; 351:1755I)
26 Antihypertensive treatment in patients with diabetes UKPDS Trial design Patients with type 2 diabetes and hypertension Randomised treatment Tight BP control (758) - mean 144/82 Less tight BP control (390) - mean 154/87 Follow up 8.4 years Diabetes related fatal and non-fatal events (UKPDS 38 Brit Med J 1998; 317: 703)
27 Antihypertensive treatment in patients with diabetes UKPDS Proportion with any fatal or non-fatal diabetes related end-point Proportion dying of diabetes related causes RR 24%; p= RR 32%; p=0.019 (UKPDS 38 Brit Med J 1998; 317: 703)
28 Antihypertensive treatment in patients with diabetes UKPDS Association between systolic blood pressure and macro- and microvascular complications of type 2 diabetes Lowest risk with systolic BP 120 mm Hg No indication of a threshold (Adler et al Brit Med J 2000; 321: 412)
29 Antihypertensive treatment in patients with diabetes ADVANCE Patients with type 2 diabetes Randomised treatment in addition to ongoing therapy Perindopril + Indapamide Placebo Trial design Follow up 4.3 years Composite major macro- and microvascular events (Patel et al Lancet 2007; 370: 829)
30 Antihypertensive treatment in patients with diabetes ADVANCE Impact on blood pressure To be noted 5.6 mm Hg (95%CI ) Entry BP (mm Hg) Mean 145/81 Syst <140 47% Diast <90 41% 2.2 mm Hg (95%CI ) (Patel et al Lancet 2007; 370: 829)
31 Cumulative mortality (%) Antihypertensive treatment in patients with diabetes ADVANCE Impact of study drug on all cause mortality HR 0.86 (95%CI ); p=0.025 Follow up (months) (Patel et al Lancet 2007; 370: 829)
32 Antihypertensive treatment in patients with diabetes ACCORD Trial design Patients with type 2 diabetes Randomised treatment in addition to ongoing therapy Intensive syst BP <120 mm Hg Standard syst BP <140 mm Hg Follow up 4.7 years Composite CV death or non-fatal MI or stroke (ACCORD Study group New Engl J Med 2010; 362: 1575)
33 Antihypertensive treatment in patients with diabetes ACCORD Blood pressure control (ACCORD Study group New Engl J Med 2010; 362: 1575)
34 Antihypertensive treatment in patients with diabetes ACCORD Outcome Primary outcome Nonfatal stroke Side effects % Intensive group 3.3 Standard group 1.3 Nonfatal Myocardial Infarction Cardiovascular death Caveats Low event rate No adjudication Open label design Treatment ad hoc (ACCORD Study group New Engl J Med 2010; 362: 1575)
35 Blood pressure targets by guidelines and CV events Experiences from ONTARGET Trial design Patients with CVD or diabetes with end organ damage Randomised treatment in addition to ongoing therapy Telmisartan 80 mg Ramipril 10 mg Combination of the two Follow up 4.6 years Mortality, CV events and hospitalisation for CHF) (Mancia Rydén et al Circulation 2011; In press)
36 (%) (%) Blood pressure targets by guidelines and CV events Experiences from ONTARGET Baseline SBP 130 mmhg by proportion of visits with BP <130/80 mmhg Proportion of visits BP <130/80 mmhg < 25% 0 8 Death, MI, Stroke or CHF (hosp) Death, MI or Stroke CV death 25 to < 50% 50 to < 75% 4 75% 0 MI CHF (hosp) Stroke (Mancia Rydén et al Circulation 2011; In press)
37 The target blood presssure in patients with diabetes is <130 mm Hg Guideline recommendations On the background to these recommendations Epidemiological information Myocardial involvement Blood pressure lowering treatment Conclusion
38 The target blood presssure in patients with diabetes is <130 mm Hg Concluding remarks on blood pressure management in patients with diabetes Check blood pressure regularly Grand conclusion Treat intensively TRUST Combine several drugs THE GUIDELINES Target <130/80 mm Hg and use common sense Individualise the approach
39 Controversies in hypertension, About Diabetes diabetes and and metabolic Cardiovascular syndrome Risk ESC annual congress August 29, 2011 The target blood pressure in patients with diabetes is <130 mm Hg Rebuttal Lars Rydén Karolinska Institutet Stockholm, Sweden
40 Multifactorial Intervention in type 2 Diabetes Euro Heart Survey Diabetes and the Heart Patients from all day practice 110 centers in 25 countries n= Coronary artery disease with or without diabetes Evidence based medicine The combined use of β-blockade, RAA-inhibition, antiplatelets and statins if not contraindicated One year follow up by management (Anselmino et al Europ J Cardiovasc Prev Rehab 2008;15:216)
41 Cumulative survival Multifactorial Intervention in type 2 Diabetes Euro Heart Survey Diabetes and the Heart Impact of Evidence Based Medicine (EBM) on 1-year mortality 1,00 0,99 0,98 0,97 0,96 0,95 0,94 0,93 0,92 0, Time of follow up (days) No DM EBM + No DM EBM - DM EBM + DM EBM - (Anselmino et al Europ J Cardiovasc Prev Rehab 2008;15:216)
42 Multifactorial Intervention in type 2 Diabetes The Steno 2 study Outcome total mortality after 13 years Cumulative incidence of death (%) Numbers at risk Conventional Intensive 70 Number 60 Log-rank of P=0.015 patients needed to treat for 13 years to avoid one Death 5 Cardiovascular death 8 Major cardiovascular event 3 Progression to nephropathy Years of follow-up (Gaede et al New Engl J Med 2008; 358: 580 ) Conventional Intensive
43 Multifactorial Intervention in type 2 Diabetes Actual contribution of individual risk factors in improving the UKPDS score in STENO 2 intensive arm HbA1c 13% Lipids 73% Total cholesterol 48% SBP 11% HDL cholesterol 25% Smoking 3% (Gaede et al Diabetes 2004; 53: S39)
44 Patient management in Clinical Practice Euro Heart Survey Diabetes and the Heart Elective consultation (58%) Diabetes 860 (30%) No diabetes (70%) (Anselmino et al Europ J Cardiovasc Prev Rehab 2007;14:28)
45 Patient management in Clinical Practice Euro Heart Survey Diabetes and the Heart Variable Target Outside Target Outside n = pat no % 2007 % Blood lipids (mmol/l) n=589 Cholesterol < n=532 LDL < n=559 HDL > n=585triglycerides < Blood pressure (mm Hg) n=746 <140/90 27 FP-glucose (mmol/l) n=573 < HbA1c (%) n=397 < (Anselmino et al Europ J Cardiovasc Prev Rehab 2008;15:216)
46 Euro Heart Survey Diabetes and the Heart Variable Target Outside Target Outside n = pat no % 2007 % Blood lipids (mmol/l) n=589 Cholesterol < < n=532 LDL < n=559 HDL A considerable > > n=585triglycerides < Blood pressure (mm (mm Hg) Hg) n=746 <140/90 27 <130/80 56 FP-glucose (mmol/l) n=573 < < HbA1c (%) Patient management in Clinical Practice improvement potential n=397 < < (Anselmino and Rydén. Data on file)
47 Controversies in hypertension, About Diabetes diabetes and and metabolic Cardiovascular syndrome Risk ESC annual congress August 29, 2011 The target blood pressure in patients with diabetes is <130 mm Hg Thanks for the attention!!!
48 Diabetes mellitus and hypertension Effects on left ventricular structure and function The STRONG Heart Study Parameter Population No DM/HT DM HT DM+HT American indians n= Age (years) No diabetes or hypertension Females (%) Diabetes only BMI Hypertension (kg/m 2 ) only BPsyst Diabetes (mmhg) and Hypertension BPdiast Method (mmhg) BP Echocardiography therapy (%) (Bella et al Am J Card 2001:87;1260)
49 Antihypertensive treatment in patients with diabetes UKPDS Proportion of patients requiring 0, 1, 2 or 3 blood pressure lowering drugs during follow up (UKPDS 38 Brit Med J 1998; 317: 703)
50 Antihypertensive treatment in patients with diabetes UKPDS Long term follow up after tight BP control Mean BP for patients assigned to tight or less tight control 10 years from the end of the study 1997 Hazard Ratios for any diabetes related end-point 10 years from the end of study 1997 (Holman et al New Engl J Med 2008; 359: 1565)
Treatment to reduce cardiovascular risk: multifactorial management
Treatment to reduce cardiovascular risk: multifactorial management Matteo Anselmino, MD PhD Assistant Professor San Giovanni Battista Hospital Division of Cardiology, Department of Internal Medicine University
More informationMaster class in preventive cardiology Focus on diabetes and cardiovascular disease Geneva April
Master class in preventive cardiology Focus on diabetes and cardiovascular disease Geneva April 14 2011 Introduction Course objectives A review of available guidelines Lars Rydén Cardiology Unit Department
More informationMaster Class in Preventive Cardiology Focus on Diabetes and Cardiovascular Disease Geneva April
Master Class in Preventive Cardiology Focus on Diabetes and Cardiovascular Disease Geneva April 14 2011 Coronary interventions in patients with diabetes Lars Rydén Karolinska Institutet Stockholm, Sweden
More informationThe Diabetes Link to Heart Disease
The Diabetes Link to Heart Disease Anthony Abe DeSantis, MD September 18, 2015 University of WA Division of Metabolism, Endocrinology and Nutrition Oswald Toosweet Case #1 68 yo M with T2DM Diagnosed DM
More informationADVANCE post trial ObservatioNal Study
Hot Topics in Diabetes 50 th EASD, Vienna 2014 ADVANCE post trial ObservatioNal Study Sophia Zoungas The George Institute The University of Sydney Rationale and Study Design Sophia Zoungas The George Institute
More informationESC GUIDELINES ON DIABETES AND CARDIOVASCULAR DISEASES
ESC GUIDELINES ON DIABETES AND CARDIOVASCULAR DISEASES Pr. Michel KOMAJDA Institute of Cardiology - IHU ICAN Pitie Salpetriere Hospital - University Pierre and Marie Curie, Paris (France) DEFINITION A
More informationDiabetes Mellitus: A Cardiovascular Disease
Diabetes Mellitus: A Cardiovascular Disease Nestoras Mathioudakis, M.D. Assistant Professor of Medicine Division of Endocrinology, Diabetes, & Metabolism September 30, 2013 1 The ABCs of cardiovascular
More informationThe Clinical Unmet need in the patient with Diabetes and ACS
The Clinical Unmet need in the patient with Diabetes and ACS Professor Kausik Ray (UK) BSc(hons), MBChB, MD, MPhil, FRCP (lon), FRCP (ed), FACC, FESC, FAHA Diabetes is a global public health challenge
More informationBlood Pressure Targets in Diabetes
Stockholm, 29 th August 2010 ESC Meeting Blood Pressure Targets in Diabetes Peter M Nilsson, MD, PhD Department of Clinical Sciences University Hospital, Malmö Sweden Studies on BP in DM2 ADVANCE RCT (Lancet
More informationTreating Hypertension in Individuals with Diabetes
Treating Hypertension in Individuals with Diabetes Copyright 2017 by Sea Courses Inc. All rights reserved. No part of this document may be reproduced, copied, stored, or transmitted in any form or by any
More informationOptimizing risk assessment of total cardiovascular risk What are the tools? Lars Rydén Professor Karolinska Institutet Stockholm, Sweden
Optimizing risk assessment of total cardiovascular risk What are the tools? Lars Rydén Professor Karolinska Institutet Stockholm, Sweden Cardiovascular Disease Prevention (CVD) Three Strategies for CVD
More informationIschemic Heart and Cerebrovascular Disease. Harold E. Lebovitz, MD, FACE Kathmandu November 2010
Ischemic Heart and Cerebrovascular Disease Harold E. Lebovitz, MD, FACE Kathmandu November 2010 Relationships Between Diabetes and Ischemic Heart Disease Risk of Cardiovascular Disease in Different Categories
More informationUpdate on CVD and Microvascular Complications in T2D
Update on CVD and Microvascular Complications in T2D Jay S. Skyler, MD, MACP Division of Endocrinology, Diabetes, and Metabolism and Diabetes Research Institute University of Miami Miller School of Medicine
More informationDiabetes and Heart Failure
Diabetes and Heart Failure A common and fatal combination A Aspects on epidemiology, prognosis diagnosis and therapy Lars Rydén Department of Medicine Karolinska Institutet Stockholm, Sweden Diabetes and
More informationT. Suithichaiyakul Cardiomed Chula
T. Suithichaiyakul Cardiomed Chula The cardiovascular (CV) continuum: role of risk factors Endothelial Dysfunction Atherosclerosis and left ventricular hypertrophy Myocardial infarction & stroke Endothelial
More informationHow to Reduce CVD Complications in Diabetes?
How to Reduce CVD Complications in Diabetes? Chaicharn Deerochanawong M.D. Diabetes and Endocrinology Unit Department of Medicine Rajavithi Hospital, Ministry of Public Health Framingham Heart Study 30-Year
More informationWhy is Earlier and More Aggressive Treatment of T2 Diabetes Better?
Blood glucose (mmol/l) Why is Earlier and More Aggressive Treatment of T2 Diabetes Better? Disclosures Dr Kennedy has provided CME, been on advisory boards or received travel or conference support from:
More informationGlycemic control a matter of life and death
Glycemic control a matter of life and death Linda Garcia Mellbin MD PhD Specialist in Cardiology & Internal medicine Dep of Cardiology Karolinska University Hospital /Karolinska Institutet Mortality (%)
More informationCedars Sinai Diabetes. Michael A. Weber
Cedars Sinai Diabetes Michael A. Weber Speaker Disclosures I disclose that I am a Consultant for: Ablative Solutions, Boston Scientific, Boehringer Ingelheim, Eli Lilly, Forest, Medtronics, Novartis, ReCor
More informationDisclosures. Diabetes and Cardiovascular Risk Management. Learning Objectives. Atherosclerotic Cardiovascular Disease
Disclosures Diabetes and Cardiovascular Risk Management Tony Hampton, MD, MBA Medical Director Advocate Aurora Operating System Advocate Aurora Healthcare Downers Grove, IL No conflicts or disclosures
More informationDiabetes Guidelines in View of Recent Clinical Trials Are They Still Applicable?
Diabetes Guidelines in View of Recent Clinical Trials Are They Still Applicable? Jay S. Skyler, MD, MACP Division of Endocrinology, Diabetes, and Metabolism and Diabetes Research Institute University of
More informationDiabete: terapia nei pazienti a rischio cardiovascolare
Diabete: terapia nei pazienti a rischio cardiovascolare Giorgio Sesti Università Magna Graecia di Catanzaro Cardiovascular mortality in relation to diabetes mellitus and a prior MI: A Danish Population
More information1. Albuminuria an early sign of glomerular damage and renal disease. albuminuria
1. Albuminuria an early sign of glomerular damage and renal disease albuminuria Cardio-renal continuum REGRESS Target organ damage Asymptomatic CKD New risk factors Atherosclerosis Target organ damage
More informationManaging HTN in the Elderly: How Low to Go
Managing HTN in the Elderly: How Low to Go Laxmi S. Mehta, MD, FACC The Ohio State University Medical Center Assistant Professor of Clinical Internal Medicine Clinical Director of the Women s Cardiovascular
More informationDiabetes and Hypertension
Diabetes and Hypertension William C. Cushman, MD, FAHA, FACP, FASH Chief, Preventive Medicine, Veterans Affairs Medical Center Professor, Preventive Medicine, Medicine, and Physiology University of Tennessee
More informationThe Metabolic Syndrome: Is It A Valid Concept? YES
The Metabolic Syndrome: Is It A Valid Concept? YES Congress on Diabetes and Cardiometabolic Health Boston, MA April 23, 2013 Edward S Horton, MD Joslin Diabetes Center Harvard Medical School Boston, MA
More informationPreventive Cardiology Scientific evidence
Preventive Cardiology Scientific evidence Professor David A Wood Garfield Weston Professor of Cardiovascular Medicine International Centre for Circulatory Health Imperial College London Primary prevention
More informationAntihypertensive Trial Design ALLHAT
1 U.S. Department of Health and Human Services Major Outcomes in High Risk Hypertensive Patients Randomized to Angiotensin-Converting Enzyme Inhibitor or Calcium Channel Blocker vs Diuretic National Institutes
More informationThe Latest Generation of Clinical
The Latest Generation of Clinical Guidelines: HTN and HLD Dave Brackett Clinical Guideline Purpose Uniform approach Awareness of key details Diagnosis Treatment Monitoring Evidence based approach Inform
More informationGuidelines on cardiovascular risk assessment and management
European Heart Journal Supplements (2005) 7 (Supplement L), L5 L10 doi:10.1093/eurheartj/sui079 Guidelines on cardiovascular risk assessment and management David A. Wood 1,2 * 1 Cardiovascular Medicine
More informationA factorial randomized trial of blood pressure lowering and intensive glucose control in 11,140 patients with type 2 diabetes
A factorial randomized trial of blood pressure lowering and intensive glucose control in 11,140 patients with type 2 diabetes Hypotheses: Among individuals with type 2 diabetes, the risks of major microvascular
More informationReview. Hyperglycemia, dyslipidemia and hypertension in older people with diabetes: the benefits of cardiovascular risk reduction
Review Hyperglycemia, dyslipidemia and hypertension in older people with diabetes: the benefits of cardiovascular risk reduction Diabetes mellitus is increasingly recognized as an essentially vascular
More informationThe Burden of the Diabetic Heart
The Burden of the Diabetic Heart Dr. Ghaida Kaddaha (MBBS, MRCP-UK, FRCP-london) Diabetes Unit Rashid Hospital Dubai U.A.E Risk of CVD in Diabetes Morbidity and mortality from CVD is 2-4 fold higher than
More informationA Fork in the Road: Navigating Through New Terrain
A Fork in the Road: Navigating Through New Terrain Carol Hatch Wysham, MD Clinical Associate Professor of Medicine University of Washington School of Medicine Section Head, Rockwood Center for Diabetes
More informationMaster Class in Preventive Cardiology. The New MI Phenotype OR. Klas Malmberg MD, PhD, FESC Karolinska Institutet, Stockholm Sweden
Master Class in Preventive Cardiology The New MI Phenotype OR Klas Malmberg MD, PhD, FESC Karolinska Institutet, Stockholm Sweden The New MI Phenotype OR Coronary disease and glucose abnormalities Klas
More informationTotal risk management of Cardiovascular diseases Nobuhiro Yamada
Nobuhiro Yamada The worldwide burden of cardiovascular diseases (WHO) To prevent cardiovascular diseases Beyond LDL Multiple risk factors With common molecular basis The Current Burden of CVD CVD is responsible
More informationDiabetes Mellitus: Implications of New Clinical Trials and New Medications
Diabetes Mellitus: Implications of New Clinical Trials and New Medications Estimates of Diagnosed Diabetes in Adults, 2005 Alka M. Kanaya, MD Asst. Professor of Medicine UCSF, Primary Care CME October
More informationFelix Vallotton Ball (1899) LDL-C management in Asian diabetes: moderate vs. high intensity statin --- a lesson from EMPATHY study
Felix Vallotton Ball (1899) LDL-C management in Asian diabetes: moderate vs. high intensity statin --- a lesson from EMPATHY study Conflict of interest disclosure None Committee of Scientific Affairs Committee
More informationAmerican Academy of Insurance Medicine
American Academy of Insurance Medicine October 2012 Dr. Alison Moy Liberty Mutual Dr. John Kirkpatrick Thrivent Financial for Lutherans 1 59 year old male, diagnosed with T2DM six months ago Nonsmoker
More informationHypertension Guidelines: Are We Pressured to Change? Oregon Cardiovascular Symposium Portland, Oregon June 6, Financial Disclosures
Hypertension Guidelines: Are We Pressured to Change? Oregon Cardiovascular Symposium Portland, Oregon June 6, 2015 William C. Cushman, MD Professor, Preventive Medicine, Medicine, and Physiology University
More informationIs there a mechanism of interaction between hypertension and dyslipidaemia?
Is there a mechanism of interaction between hypertension and dyslipidaemia? Neil R Poulter International Centre for Circulatory Health NHLI, Imperial College London Daegu, Korea April 2005 Observational
More informationT2 Diabetes in Sep-16. Stephen Leow Disclosures. Why do we treat diabetes? Agenda. Targets
Stephen Leow Disclosures I have received honoraria, sat on the advisory boards or received grants from Novo Nordisk, Sanofi Aventis, Eli Lilly, Boehringer Ingleheim, Jansenn Cilag, Mundipharma, BioCSL,
More informationEnvironmental. Vascular / Tissue. Metabolics
Global Risk Reduction--WINS Picking Mom and Dad-2016 Environmental Vascular / Tissue Metabolics Stop smoking-1b Physical activity-1b Weight control-1b Chelation therapy-3c Influenza vaccination-1b Blood
More informationΑΡΥΙΚΗ ΠΡΟΔΓΓΙΗ ΤΠΔΡΣΑΙΚΟΤ ΑΘΔΝΟΤ. Μ.Β.Παπαβαζιλείοσ Καρδιολόγος FESC - Γιεσθύνηρια ιζμανόγλειον ΓΝΑ Clinical Hypertension Specialist ESH
ΑΡΥΙΚΗ ΠΡΟΔΓΓΙΗ ΤΠΔΡΣΑΙΚΟΤ ΑΘΔΝΟΤ Μ.Β.Παπαβαζιλείοσ Καρδιολόγος FESC - Γιεσθύνηρια ιζμανόγλειον ΓΝΑ Clinical Hypertension Specialist ESH Hypertension Co-Morbidities HTN Commonly Clusters with Other Risk
More informationACCORD, ADVANCE & VADT. Now what do I do in my practice?
ACCORD, ADVANCE & VADT Now what do I do in my practice? Richard M. Bergenstal, MD International Diabetes Center Park Nicollet Health Services University of Minnesota Minneapolis, MN richard.bergenstal@parknicollet.com
More informationDiabetes new challenges, new agents, new order
Diabetes new challenges, new agents, new order Ken Earle St Georges University Hospitals NHS Foundation Trust Overview Cardiovascular disease unmet needs Treating evident and residual risk Integrating
More informationJNC 8 -Controversies. Sagren Naidoo Nephrologist CMJAH
JNC 8 -Controversies Sagren Naidoo Nephrologist CMJAH Joint National Committee (JNC) Panel appointed by the National Heart, Lung, and Blood Institute (NHLBI) First guidelines (JNC-1) published in 1977
More informationCANADIAN STROKE BEST PRACTICE RECOMMENDATIONS. Prevention of Stroke Evidence Tables Diabetes Management
CANADIAN STROKE BEST PRACTICE RECOMMENDATIONS Diabetes Management Coutts S, Wein T (Writing Group Chairs) on Behalf of the PREVENTION of STROKE Writing Group 2014 Heart and Stroke Foundation November 2014
More informationDiabetes and Cardiovascular Risk Management Denise M. Kolanczyk, PharmD, BCPS-AQ Cardiology
Diabetes and Cardiovascular Risk Management Denise M. Kolanczyk, PharmD, BCPS-AQ Cardiology Disclosures In compliance with the accrediting board policies, the American Diabetes Association requires the
More informationALLHAT. ALLHAT Antihypertensive Trial Results by Baseline Diabetic & Fasting Glucose Status
ALLHAT Antihypertensive Trial Results by Baseline Diabetic & Fasting Glucose Status 1 Introduction and Background Clinical trials have reported reduction in CV events with diuretics, CCBs, ACE inhibitors,
More informationCardiovascular Management of a Patient with Diabetes
Cardiovascular Management of a Patient with Diabetes Dr Jeremy Krebs Clinical Leader Endocrinology and Diabetes Wellington Hospital Summary People with diabetes take a lot of medication Compliance and
More informationBlood Pressure Treatment Goals
Blood Pressure Treatment Goals Kenneth Izuora, MD, MBA, FACE Associate Professor UNLV School of Medicine November 18, 2017 Learning Objectives Discuss the recent studies on treating hypertension Review
More informationCVD Risk Assessment. Michal Vrablík Charles University, Prague Czech Republic
CVD Risk Assessment Michal Vrablík Charles University, Prague Czech Republic What is Risk? A cumulative probability of an event, usually expressed as percentage e.g.: 5 CV events in 00 pts = 5% risk This
More informationHYPERTENSION GUIDELINES WHERE ARE WE IN 2014
HYPERTENSION GUIDELINES WHERE ARE WE IN 2014 Donald J. DiPette MD FACP Special Assistant to the Provost for Health Affairs Distinguished Health Sciences Professor University of South Carolina University
More informationHypertension targets: sorting out the confusion. Brian Rayner, Division of Nephrology and Hypertension, University of Cape Town
Hypertension targets: sorting out the confusion Brian Rayner, Division of Nephrology and Hypertension, University of Cape Town Historical Perspective The most famous casualty of this approach was the
More informationHypertension and Diabetes Should we be SPRINTING or Reaching an ACCORD?
Hypertension and Diabetes Should we be SPRINTING or Reaching an ACCORD? Suzanne Oparil, MD Distinguished Professor of Medicine, Professor of Cell, Developmental and Integrative Biology Director, Vascular
More informationShould we prescribe aspirin and statins to all subjects over 65? (Or even all over 55?) Terje R.Pedersen Oslo University Hospital Oslo, Norway
Should we prescribe aspirin and statins to all subjects over 65? (Or even all over 55?) Terje R.Pedersen Oslo University Hospital Oslo, Norway The Polypill A strategy to reduce cardiovascular disease by
More informationMacrovascular Residual Risk. What risk remains after LDL-C management and intensive therapy?
Macrovascular Residual Risk What risk remains after LDL-C management and intensive therapy? Defining Residual Vascular Risk The risk of macrovascular events and microvascular complications which persists
More informationNew Recommendations for the Treatment of Hypertension: From Population Salt Reduction to Personalized Treatment Targets
New Recommendations for the Treatment of Hypertension: From Population Salt Reduction to Personalized Treatment Targets Sidney C. Smith, Jr. MD, FACC, FAHA Professor of Medicine/Cardiology University of
More informationYuqing Zhang, M.D., FESC Department of Cardiology, Fu Wai Hospital. CAMS & PUMC, Beijing, China
What Can We Learn from the Observational Studies and Clinical Trials of Prehypertension? Yuqing Zhang, M.D., FESC Department of Cardiology, Fu Wai Hospital. CAMS & PUMC, Beijing, China At ARIC visit 4
More informationDiabetes and the Heart
Diabetes and the Heart Jeffrey Boord, MD, MPH Advances in Cardiovascular Medicine Kingston, Jamaica December 6, 2012 Outline Screening for diabetes in patients with CAD Screening for CAD in patients with
More informationTreating Hypertension in 2018: What Makes the Most Sense Today?
Treating Hypertension in 2018: What Makes the Most Sense Today? Daniel Blanchard, MD Professor of Medicine UC San Diego Cardiovascular Center La Jolla, California 1 2 Speaker Disclosures Consultant and/or
More informationALLHAT Role of Diuretics in the Prevention of Heart Failure - The Antihypertensive and Lipid- Lowering Treatment to Prevent Heart Attack Trial
1 ALLHAT Role of Diuretics in the Prevention of Heart Failure - The Antihypertensive and Lipid- Lowering Treatment to Prevent Heart Attack Trial Davis BR, Piller LB, Cutler JA, et al. Circulation 2006.113:2201-2210.
More informationManagement of cardiovascular disease. Acute coronary syndromes and intensive care. Lars Rydén Karolinska Institutet Stockholm, Sweden
Management of cardiovascular disease Acute coronary syndromes and intensive care Lars Rydén Karolinska Institutet Stockholm, Sweden Hyperglycemia and acute coronary syndromes Changing fenotype GAMI Study
More informationHYPERTENSION MANAGEMENT IN ELDERLY POPULATIONS
HYPERTENSION MANAGEMENT IN ELDERLY POPULATIONS Michael J. Scalese, PharmD, BCPS, CACP Assistant Clinical Professor Auburn University Harrison School of Pharmacy July 14, 2018 DISCLOSURE/CONFLICT OF INTEREST
More informationIdentification of subjects at high risk for cardiovascular disease
Master Class in Preventive Cardiology Focus on Diabetes and Cardiovascular Disease Geneva April 14 2011 Identification of subjects at high risk for cardiovascular disease Lars Rydén Karolinska Institutet
More informationTop 5 (Topics) Papers In GIM Rocky Mountain ACP Internal Medicine Meeting Raj Padwal November 13, 2008
Top 5 (Topics) Papers In GIM 2008 Rocky Mountain ACP Internal Medicine Meeting Raj Padwal November 13, 2008 Methods Searched ACPJC/EBM, TOC of top medical journals, MEDSCAPE Best Evidence, consultation
More informationEugene Barrett M.D., Ph.D. University of Virginia 6/18/2007. Diagnosis and what is it Glucose Tolerance Categories FPG
Diabetes Mellitus: Update 7 What is the unifying basis of this vascular disease? Eugene J. Barrett, MD, PhD Professor of Internal Medicine and Pediatrics Director, Diabetes Center and GCRC Health System
More informationNew Lipid Guidelines. PREVENTION OF CARDIOVASCULAR DISEASE IN WOMEN: Implications of the New Guidelines for Hypertension and Lipids.
PREVENTION OF CARDIOVASCULAR DISEASE IN WOMEN: Implications of the New Guidelines for Hypertension and Lipids Robert B. Baron MD MS Professor and Associate Dean UCSF School of Medicine Disclosure No relevant
More informationSlide 1. Slide 2. Slide 3. A Fork in the Road: Navigating Through New Terrain. Diabetes Standards of Care Then and Now
Slide 1 A Fork in the Road: Navigating Through New Terrain Carol Hatch Wysham, MD Clinical Associate Professor of Medicine University of Washington School of Medicine Section Head, Rockwood Center for
More informationALLHAT. Major Outcomes in High Risk Hypertensive Patients Randomized to Angiotensin-Converting Enzyme Inhibitor or Calcium Channel Blocker vs Diuretic
1 U.S. Department of Health and Human Services National Institutes of Health Major Outcomes in High Risk Hypertensive Patients Randomized to Angiotensin-Converting Enzyme Inhibitor or Calcium Channel Blocker
More informationBlood Pressure Targets: Where are We Now?
Blood Pressure Targets: Where are We Now? Diana Cao, PharmD, BCPS-AQ Cardiology Assistant Professor Department of Clinical & Administrative Sciences California Northstate University College of Pharmacy
More informationPractical Diabetes. Nic Crook. (and don t use so many charts) Kuirau Specialists 1239 Ranolf Street Rotorua. Rotorua Hospital Private Bag 3023 Rotorua
Practical Diabetes (and don t use so many charts) Nic Crook Rotorua Hospital Private Bag 3023 Rotorua Kuirau Specialists 1239 Ranolf Street Rotorua Worldwide rates of diabetes mellitus: predictions 80
More informationSafety of Anacetrapib in Patients with or
Safety of Anacetrapib in Patients with or at Risk for Coronary Heart Disease Christopher P. Cannon, MD, Sukrut Shah, PhD, RPh, Hayes M. Dansky, MD, Michael Davidson, MD, Eliot A. Brinton, MD, Antonio M.
More informationCardiovascular Complications of Diabetes
VBWG Cardiovascular Complications of Diabetes Nicola Abate, M.D., F.N.L.A. Professor and Chief Division of Endocrinology and Metabolism The University of Texas Medical Branch Galveston, Texas Coronary
More informationPrevenzione cardiovascolare e cambiamento degli stili di vita. Gian Franco Gensini
Prevenzione cardiovascolare e cambiamento degli stili di vita Gian Franco Gensini Main causes of death worldwide at all ages (year:: 2005) 17.5 milion Preventing Chronic Diseases A vital investiment. WHO
More informationOral Hypoglycemics and Risk of Adverse Cardiac Events: A Summary of the Controversy
Oral Hypoglycemics and Risk of Adverse Cardiac Events: A Summary of the Controversy Jeffrey Boord, MD, MPH Advances in Cardiovascular Medicine Kingston, Jamaica December 7, 2012 VanderbiltHeart.com Outline
More informationHypertension in the Elderly. John Puxty Division of Geriatrics Center for Studies in Aging and Health, Providence Care
Hypertension in the Elderly John Puxty Division of Geriatrics Center for Studies in Aging and Health, Providence Care Learning Objectives Review evidence for treatment of hypertension in elderly Consider
More informationMetformin should be considered in all patients with type 2 diabetes unless contra-indicated
November 2001 N P S National Prescribing Service Limited PPR fifteen Prescribing Practice Review PPR Managing type 2 diabetes For General Practice Key messages Metformin should be considered in all patients
More informationDysglycaemia and Hypertension. Dr E M Manuthu Physician Kitale
Dysglycaemia and Hypertension Dr E M Manuthu Physician Kitale None Disclosures DM is MI equivalent MR FIT Objective was to assess predictors of CVD mortality among men with and without diabetes and
More informationShould I use statins?
I know the trials in heart failure but how do I manage my patient? Should I use statins? Aldo P Maggioni, MD, FESC ANMCO Research Center Firenze, Italy Disclosures Aldo P Maggioni served as a member of
More informationSystolic Blood Pressure Intervention Trial (SPRINT)
09:30-09:50 2016.4.15 Systolic Blood Pressure Intervention Trial (SPRINT) IN A NEPHROLOGIST S VIEW Sejoong Kim Seoul National University Bundang Hospital Current guidelines for BP control Lowering BP
More informationIndividualized Treatment Goals for Optimal Long-Term Health Outcomes among Patients with Type 2 Diabetes Mellitus
1 Dissertation Title Page: Individualized Treatment Goals for Optimal Long-Term Health Outcomes among Patients with Type 2 Diabetes Mellitus Qian Shi, MPH, PhD candidate Department of Global Health Management
More informationHypertension and the SPRINT Trial: Is Lower Better
Hypertension and the SPRINT Trial: Is Lower Better 8th Annual Orange County Symposium on Cardiovascular Disease Prevention Saturday, October 8, 2016 Keith C. Norris, MD, PhD, FASN Professor of Medicine,
More informationDecline in CV-Mortality
Lipids id 2013 What s Changed? Christopher Granger, MD Disclosure Research contracts: AstraZeneca, GSK, Merck, Sanofi- Aventis, BMS, Pfizer, The Medicines Company, Medtronic Foundation, and Boehringer
More informationMedication Adherence and Outcomes in High Risk Cardiovascular Patients in the ONTARGET Trial
Medication Adherence and Outcomes in High Risk Cardiovascular Patients in the ONTARGET Trial M. Böhm, H. Schumacher, U. Laufs, P. Sleight, R. Schmieder, T. Unger, K. Koon, S. Yusuf on behalf of the ONTARGET-Investigators
More informationMedication Adherence and Outcomes in High Risk Cardiovascular Patients in the ONTARGET Trial
Medication Adherence and Outcomes in High Risk Cardiovascular Patients in the ONTARGET Trial M. Böhm, H. Schumacher, U. Laufs, P. Sleight, R. Schmieder, T. Unger, K. Koon, S. Yusuf on behalf of the ONTARGET-Investigators
More informationThe Indian Polycap Study 1 & 2 (TIPS 1 & 2) and The International Polycap Study 3 & 4 (TIPS 3 & 4)
The Indian Polycap Study 1 & 2 (TIPS 1 & 2) and The International Polycap Study 3 & 4 (TIPS 3 & 4) Denis Xavier MD, MSc Professor and Head, Pharmacology, St. John's Medical College Coordinator, Division
More informationHypertension Update Clinical Controversies Regarding Age and Race
Hypertension Update Clinical Controversies Regarding Age and Race Allison Helmer, PharmD, BCACP Assistant Clinical Professor Auburn University Harrison School of Pharmacy July 22, 2017 DISCLOSURE/CONFLICT
More informationHypertension Update 2009
Hypertension Update 2009 New Drugs, New Goals, New Approaches, New Lessons from Clinical Trials Timothy C Fagan, MD, FACP Professor Emeritus University of Arizona New Drugs Direct Renin Inhibitors Endothelin
More informationMacrovascular Disease in Diabetes
Macrovascular Disease in Diabetes William R. Hiatt, MD Professor of Medicine/Cardiology University of Colorado School of Medicine President, CPC Clinical Research Conflicts CPC Clinical Research (University-based
More informationCardiovascular disease - from management to prevention
Cardiovascular disease - from management to prevention Reflections originating from the Fourth Joint European Societies Task Force on Cardiovascular Disease Prevention in Clinical Practice 2007 WHAT IS
More informationPredicting and changing the future for people with CKD
Predicting and changing the future for people with CKD I. David Weiner, M.D. Co-holder, C. Craig and Audrae Tisher Chair in Nephrology Professor of Medicine and Physiology and Functional Genomics University
More informationKidney and heart: dangerous liaisons. Luis M. RUILOPE (Madrid, Spain)
Kidney and heart: dangerous liaisons Luis M. RUILOPE (Madrid, Spain) Type 2 diabetes and renal disease: impact on cardiovascular outcomes The "heavyweights" of modifiable CVD risk factors Hypertension
More informationManaging Hypertension in Diabetes Sean Stewart, PharmD, BCPS, BCACP, CLS Internal Medicine Park Nicollet Clinic St Louis Park.
Managing Hypertension in Diabetes 2015 Sean Stewart, PharmD, BCPS, BCACP, CLS Internal Medicine Park Nicollet Clinic St Louis Park Case Scenario Mike M is a 59 year old man with type 2 diabetes managed
More informationImplications of The LookAHEAD Trial: Is Weight Loss Beneficial for Patients with Diabetes?
Implications of The LookAHEAD Trial: Is Weight Loss Beneficial for Patients with Diabetes? Boston, MA November 7, 213 Edward S. Horton, MD Professor of Medicine Harvard Medical School Senior Investigator
More informationThe problem of uncontrolled hypertension
(2002) 16, S3 S8 2002 Nature Publishing Group All rights reserved 0950-9240/02 $25.00 www.nature.com/jhh The problem of uncontrolled hypertension Department of Public Health and Clinical Medicine, Norrlands
More informationIn the Literature 1001 BP of 1.1 mm Hg). The trial was stopped early based on prespecified stopping rules because of a significant difference in cardi
Is Choice of Antihypertensive Agent Important in Improving Cardiovascular Outcomes in High-Risk Hypertensive Patients? Commentary on Jamerson K, Weber MA, Bakris GL, et al; ACCOMPLISH Trial Investigators.
More informationJUPITER NEJM Poll. Panel Discussion: Literature that Should Have an Impact on our Practice: The JUPITER Study
Panel Discussion: Literature that Should Have an Impact on our Practice: The Study Kaiser COAST 11 th Annual Conference Maui, August 2009 Robert Blumberg, MD, FACC Ralph Brindis, MD, MPH, FACC Primary
More informationCVD risk assessment using risk scores in primary and secondary prevention
CVD risk assessment using risk scores in primary and secondary prevention Raul D. Santos MD, PhD Heart Institute-InCor University of Sao Paulo Brazil Disclosure Honoraria for consulting and speaker activities
More information